Eli Lilly’s drug is latest failure in search for treatment to slow Alzheimer’s

Eli Lilly and Co. building
This 2011 file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly said Wednesday that its potential Alzheimer'€™s treatment, solanezumab, failed in another large clinical study.
(AP Photo/Darron Cummings, File)

An experimental treatment for Alzheimer’s failed again in a widely anticipated study, disappointing many who had hoped drugmaker Eli Lilly had finally found a way to slow the progression of the mind-robbing disease. 

The drug did not work better than a placebo treatment in a study of more than 2,100 people with mild Alzheimer’s, the company announced Wednesday. 

Alzheimer’s experts had modest expectations for the drug, called solanezumab. It had already failed in two large studies in people with mild-to-moderate forms of the disease. Combined results, however, suggested that the drug might work for those with the mildest symptoms. 

Lilly started another study, testing monthly infusions of the drug for 18 months in those patients. 


The drug binds to a protein called amyloid that builds up in the brains of Alzheimer’s patients. The drug clears the protein from the brain before it can clump together to form a sticky plaque between nerve cells. Researchers think the protein triggers the degenerative disease, which impairs memory and thought. 

“When you get a result like this you have to question, is it the stage of the disease, is it the particular drug you are testing, or is it some combination? Or is the strategy wrong?” said Dr. Stephen Salloway, neurology chief at Brown University in Providence, Rhode Island. “We don’t know the answer.” 

Lilly’s drug is still being studied in two other major tests. One involves patients with a rare, inherited form of Alzheimer’s, and the other is a prevention trial of people who have no symptoms but have deposits of amyloid in their brain as seen on scans. 

At least 18 other drugs are in late-stage testing, including several similar to solanezumab. Dietary therapies, supplements and even a medical device also are being tried. 


Lilly has spent about $3 billion over the past 27 years on Alzheimer’s research. One of the drugmaker’s researchers, Dr. Eric Siemers, said the latest results were a “bump in the road,” and scientists are looking forward to learning more from the results of other potential treatments. 

“We’re continuing to go forward, it’s just not as fast as we would like,” said Siemers. 

With more than 5 million people in the United States afflicted, Alzheimer’s is the most common form of dementia. There’s no known way to prevent, cure or even slow its progression. 

Wall Street analysts had given Lilly’s drug relatively low odds of success. Even so, shares of Indianapolis-based Eli Lilly and Co. plunged more than 10%, or $8.02, to $67.97 Wednesday afternoon. Shares of other drugmakers researching Alzheimer’s treatments, like Biogen Inc., also sank in early trading. 

Get our weekly California Inc. newsletter